HEOR

News

NICE backs first targeted therapy for ALK+ lung cancer

Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication.

News

NICE turns down Takeda colorectal cancer drug

Takeda's recently approved advanced colorectal cancer therapy Fruzaqla has been rejected by NICE for use by the NHS on the grounds that it is not cost-effective.

News

Roche's PNH drug PiaSky backed for NHS use by NICE

Roche's PiaSky has been recommended for use by the NHS in England and Wales for the rare blood disorder paroxysmal nocturnal haemoglobinuria (PNH), becoming the first option for patients th

News

ICER mulls GSK COPD drugs ahead of next Medicare negotiation

The list for the next round of medicines that will be subject to Medicare price negotiations isn’t in yet, but the Institute for Clinical and Economic Review (ICER) reckons a chronic obstru

News

Daiichi Sankyo's Vanflyta gets NICE nod for leukaemia

Daiichi Sankyo's FLT3 inhibitor Vanflyta has been recommended for NHS use as a treatment for a specific form of acute myeloid leukaemia (AML) in England and Wales, the first countries in Eu

News

NICE clears NHS use of MSD's Welireg for genetic disorder

Patients in England and Wales with a rare genetic disorder will soon be able to access treatment with MSD's Welireg via the NHS, nearly a year after their counterparts in Scotland.